The second half of this decade will put the Bristol Myers Squibb management team to the test as the company prepares for losses of exclusivity (LOEs) for its three top-selling products by launching up to 10 new drugs and as many as 30 new indications for its approved medicines between 2025 and 2030. That is on top of brand names added to the BMS product roster earlier this decade, including Sotyktu (deucravacitinib), Camzyos (mavacamten) and Reblozyl (luspatercept).
BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches
2025-2030 Could Bring 10 NMEs, 30 Added Indications
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.
